Gritstone Bio is laying off 40% of employees after delaying the start of a phase 2 trial testing its COVID-19 vaccine, which in turn pushed back the receipt of federal funds. The layoffs announced ...

Gritstone bio Inc (NASDAQ:GRTS) shares are trading lower after the company announced an approximately 40% reduction of its workforce. The move comes following the recently announced delay of the ...

Gritstone Bio (NASDAQ:GRTS) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a concise overview of ...

Gritstone bio's (GRTS) strength lies in its best-in-class antigen prediction, driven by a proprietary artificial intelligence (AI) platform called EDGE. This platform enables the identification of ...

-- Newly developed EDGE-II model achieves superior predictive performance of HLA Class II presentation and CD4+ immunogenicity over publicly available models -- -- Combined with Gritstone's vaccine ...

(Reuters) - Gritstone bio Inc said on Tuesday it had entered into a funding agreement of up to $20.6 million with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance its vaccine ...

EMERYVILLE, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight ...

This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview of the expected readout from Gritstone Bio’s neoantigen cancer vaccine study. Before the end of the ...

--Gritstone to Host Conference Call Today at 8:00 a.m. ET-- EMERYVILLE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company ...

EMERYVILLE, Calif.--(BUSINESS WIRE)--Gritstone Oncology, a next-generation personalized cancer immunotherapy company, today announced the successful completion of a $92.7 million Series B preferred ...

Gritstone bio is the latest drug developer to be tapped for the Biomedical Advanced Research and Development Authority’s (BARDA's) Project NextGen, with the biotech in line for more than $400 million ...